Continuing Medical Education Questions: November 2021

Area of Science:

• Hepatology
• Gastroenterology
• Clinical Pharmacology

Background:

• Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease.
• Ursodeoxycholic acid is the first-line treatment, but many patients have an inadequate response.
• Obeticholic acid and fibrates are second-line treatment options, but comparative data are limited.

Purpose of the Study:

• To compare the efficacy and safety of obeticholic acid and fibrates in patients with primary biliary cholangitis.
• To evaluate treatment outcomes based on biochemical markers and clinical endpoints.

Main Methods:

• Multicentric observational study.
• Retrospective analysis of patient data from multiple liver centers.
• Inclusion of patients with primary biliary cholangitis treated with either obeticholic acid or fibrates.
• Assessment of biochemical parameters (e.g., alkaline phosphatase, bilirubin) and adverse events.

Main Results:

• Both obeticholic acid and fibrates demonstrated significant improvements in liver biochemistry.
• No significant differences were observed in the overall efficacy between the two treatment groups.
• Specific safety profiles were noted for each drug, requiring careful patient monitoring.

Conclusions:

• Obeticholic acid and fibrates represent effective therapeutic options for patients with primary biliary cholangitis.
• Treatment choice may depend on individual patient characteristics and safety considerations.
• Further prospective studies are warranted to confirm these findings and optimize treatment strategies.